• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1308611 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
" @/ y( T0 ]5 DNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, c% p# }" b% b/ W1 C4 h, \* Y  M+ Author Affiliations
( M, j7 _* ~, m0 E; F  I
8 s1 }! w+ k2 o/ m* i! B1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ! F5 c/ j" T: j- u
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
- p# S- X8 W3 Y# K; s7 b5 ^3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* r: p; v' |. Z* b; E; O$ D4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
) N1 p+ _' r0 z" Z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 b& O$ x- |" c" d, p2 [6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 U/ Q2 @0 I$ b2 P: W+ A6 F7Kinki University School of Medicine, Osaka 589-8511, Japan ' |7 V% b" g: d; `% c' C
8Izumi Municipal Hospital, Osaka 594-0071, Japan ' f9 z" z) C8 J: D. ]
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
4 c5 u( w$ m" {. S$ _- r2 Q! tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp / h% N9 s& g5 V" F8 {+ z( q
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
4 n, z" b+ H0 o2 G: m
& \, r0 M8 s: E) u3 D* S7 ]3 G0 H
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ) n2 H) l6 G5 E9 u, K
! {, K; q  L2 |  n- g  E
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato , a/ l! c/ G% O3 [6 i' T9 ?% H* n# l

! z8 e8 F5 E5 c! Q+ UAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
5 d- G- v5 L6 j* k( u
+ H3 @5 J. Y( n: h' pPublished online on: Thursday, December 1, 2011 ( n4 T6 f' p+ |# P/ v( C

8 }5 Q* @+ Q0 Z, S+ i$ CDoi: 10.3892/ol.2011.507 2 D, R1 C% a7 Q$ v/ ?2 x

: U: H7 f2 t* C, r( BPages: 405-410
) o3 {6 P& o5 K$ o9 `5 \7 J$ o" x: g9 j( A' x
Abstract:
, f+ T& I4 o6 t' ?S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.4 M; [& ~0 H; l2 p7 V+ D% C: W; V

! d  @0 Y. |( _" c4 u+ e2 x
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population% H$ k9 v( [& t" M% n3 d# |
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 3 X3 ^3 f7 ^  N6 A
+ Author Affiliations
- n4 Z# N. q7 u1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
$ m- J% D( t6 `7 d2 F8 i& f2Department of Thoracic Surgery, Kyoto University, Kyoto , ~# i% H# l/ y, T* q3 r+ Y( M
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan : }2 K5 J+ m. ?" F
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 2 h, C3 \9 S- @) S, L% t- @; s9 X
Received September 3, 2010. ) w8 H# L9 s% U: K
Revision received November 11, 2010. & n8 O" R4 Z* A+ R" H/ @
Accepted November 17, 2010.
! V6 u; Q# k, s' fAbstract, P0 K; ]! m! g! r2 f* i% W
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ) q% Z4 m% @2 t9 J
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
3 D7 ^1 O6 R- R2 z8 JResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
$ b5 y2 Y# t, \5 iConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. + M! t. }0 w6 s; P1 V
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
* |4 E+ n5 j1 w7 M今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
4 U5 N% @& h  Z. c* S
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
5 b" Z# t! S+ F- n1 lhttp://clinicaltrials.gov/ct2/show/NCT01523587
2 Y9 T4 V4 _( e) s
# Y3 [" ~# v) T! K0 s( O8 C8 M* CBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC8 N- V1 O4 g- g" l
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
6 l/ q3 |- P  c9 e; k+ y- ^( M. s
- ?, s0 B1 k2 h! ^5 a2 r4 e& ^从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
2 s+ u( ^! P9 j1 A: L3 x至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 $ x% A3 y# H( u6 @( t2 D2 Y  U5 |
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
, c, N1 P. R) E8 n# q; m  p  q+ h至今为止,未出 ...

/ K! r/ o, u  H$ \没有副作用是第一追求,效果显著是第二追求。
( ~: P; u0 t+ s2 Q+ A2 N不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表